Cargando…

Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive Aspergillosis

BACKGROUND AND OBJECTIVE: A double-blind phase 3 study was conducted to compare posaconazole 300 mg intravenously (IV)/300 mg orally once daily (twice daily day 1) with voriconazole 4 mg/kg IV twice daily/200 mg orally twice daily (6 mg/kg day 1) for treatment of invasive aspergillosis. This analysi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maertens, Johan A., Rahav, Galia, Lee, Dong-Gun, Haider, Shariq, Ramirez-Sanchez, Isabel Cristina, Klimko, Nikolai, Ponce-de-León, Alfredo, Han, Seongah, Wrishko, Rebecca, Winchell, Gregory A., Grandhi, Anjana, Waskin, Hetty
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514181/ https://www.ncbi.nlm.nih.gov/pubmed/37676612 http://dx.doi.org/10.1007/s40261-023-01282-7

Ejemplares similares

1558. A Population Pharmacokinetic Model for Posaconazole Intravenous Solution and Oral Powder for Suspension Formulations in Pediatric Patients With Neutropenia
por: Winchell, Gregory A, et al.
Publicado: (2019)

1169. In Vitro Activity of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults Enrolled in a Clinical Trial
por: Castanheira, Mariana, et al.
Publicado: (2020)

Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis-review of the literature
por: Sandherr, M, et al.
Publicado: (2011)

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011)

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease
por: Cornely, Oliver A., et al.
Publicado: (2016)

Posaconazole achieves prompt recovery of voriconazole-induced liver injury in a case of invasive aspergillosis
por: Martínez-Casanova, Javier, et al.
Publicado: (2018)

Comparison of clinical pharmacology of voriconazole and posaconazole
por: Sienkiewicz, Beata M., et al.
Publicado: (2016)

358. Comparison of Voriconazole (VORI), Isavuconazole (ISAV), and Posaconazole (POSA) in the Initial Treatment of Patients With Invasive Aspergillosis (IA)
por: Cheng, Matthew P, et al.
Publicado: (2018)

1161. Effectiveness of Posaconazole in the Treatment of Rare Invasive Fungal Infections: A Systematic Literature Review
por: Bernauer, Mark, et al.
Publicado: (2020)

The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib
por: Nyga, Rémy, et al.
Publicado: (2019)

Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study
por: Yi, Whitley M., et al.
Publicado: (2017)

A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia
por: Arrieta, Antonio C., et al.
Publicado: (2019)

Voriconazole-refractory invasive aspergillosis
por: Park, Se Yoon, et al.
Publicado: (2017)

Treatment of Disseminated Aspergillosis with Posaconazole in 10 Dogs
por: Corrigan, V.K., et al.
Publicado: (2016)

702. Hepatic Safety Among Patients Treated with Anti-Fungal Triazole Agent Posaconazole: Characterization of Adverse events in a Manufacturer’s Safety Database
por: Zhou, Yun-Ping, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

The Effect of Posaconazole, Itraconazole and Voriconazole in the Culture Medium on Aspergillus fumigatus Triazole Resistance
por: Mroczyńska, Martyna, et al.
Publicado: (2020)

Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis
por: Leelawattanachai, Pannee, et al.
Publicado: (2019)

Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain
por: Grau, Santiago, et al.
Publicado: (2016)

Orbital Aspergillosis: Voriconazole – The New Standard Treatment?
por: Ohlstein, Derek H., et al.
Publicado: (2012)

Antifungal prophylactic effectiveness and intrapulmonary concentrations of voriconazole versus posaconazole in lung transplant recipients
por: Ju, Chunrong, et al.
Publicado: (2022)

Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia
por: Tu, Songji, et al.
Publicado: (2023)

1148. Activity of Posaconazole and Comparator Antifungal agents Tested Against Filamentous Fungi
por: Castanheira, Mariana, et al.
Publicado: (2020)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary Aspergillosis
por: Sarfati, Sacha, et al.
Publicado: (2022)

Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center
por: Van Matre, Edward T., et al.
Publicado: (2019)

Itraconazole, Voriconazole, and Posaconazole CLSI MIC Distributions for Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates
por: Buil, Jochem B., et al.
Publicado: (2018)

Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
por: Sime, Fekade B., et al.
Publicado: (2018)

A Review of Population Pharmacokinetic Models of Posaconazole
por: Ding, Qin, et al.
Publicado: (2022)

Management of invasive aspergillosis in patients with COPD: Rational use of voriconazole
por: Ader, Florence, et al.
Publicado: (2009)

Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial
por: Cadranel, J., et al.
Publicado: (2012)

Safety, Tolerability, and Pharmacokinetics (PK) of Posaconazole (POS) Intravenous (IV) Solution and Oral Powder for Suspension in Children With Neutropenia
por: Groll, Andreas H, et al.
Publicado: (2017)

Interaction between posaconazole and flucloxacillin in a lung transplant patient: decrease in plasma exposure of posaconazole and possible undertreatment of invasive aspergillosis: case report
por: Verfaillie, Saartje, et al.
Publicado: (2022)

High‐dose posaconazole for azole‐resistant aspergillosis and other difficult‐to‐treat mould infections
por: Schauwvlieghe, Alexander F. A. D., et al.
Publicado: (2019)

Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children
por: Boonsathorn, Sophida, et al.
Publicado: (2018)

External evaluation of published population pharmacokinetic models of posaconazole
por: Huang, Shuqi, et al.
Publicado: (2022)

Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats
por: Shen, Jiquan, et al.
Publicado: (2020)

A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model
por: Wang, Taotao, et al.
Publicado: (2018)

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
por: Döring, M., et al.
Publicado: (2013)

Primary or Secondary Prophylaxis with Voriconazole Compared with Posaconazole for Prevention of Invasive Fungal Infections After Hematopoietic Stem Cell Transplantation
por: Jansen, Jeffrey W, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mhhpe2bamt9qb2qv6o0g8smtg4